Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTM-3566 dose-escalation trial in relapsed/refractory mature B-cell lymphoma and advanced solid tumors
ISRCTN15438979Phase 2Terminated
- Sponsor
- Bantam Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BTM-3566 in mature B-cell lymphoma and Nonhematologic neoplasms (2 cohorts), sponsored by Bantam Pharmaceutical. Primary endpoint: Dose-limiting toxicity. Started Apr 2025; status: terminated.
02
Drugs
BTM-3566
03
Conditions
mature B-cell lymphomaNonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN15438979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15438979.